Table 2.

Patient characteristics

Variable	Value
Age, years	62.9 ± 9.7
Sex
Male:female	26:2
Complications
Hypertension, n (%)	10 (36%)
Diabetes, n (%)	7 (25%)
Heart failure, n (%)	3 (11%)
Respiratory disease, n (%)	0 (0%)
Therapy for pollinosis*
Second-generation antihistamine monotherapy, n (%)	6 (21%)
Internasal corticosteroids monotherapy, n (%)	4 (14%)
Second-generation antihistamine and internasal corticosteroids combined therapy, n (%)	17 (61%)
Second-generation antihistamine and anti-LTs agent combined therapy, n (%)	1 (4%)
AHI at OSA diagnosis (events/hour)	49.0 ± 21.7
Duration of CPAP use (years)	6.1 ± 3.5
PSQI score	5.6 ± 3.2
ESS score	6.9 ± 4.0

N = 28. Values are expressed as mean ± SD or median

^*As second-generation antihistamine agents, loratadine was administered to 1 patient, epinastine hydrochloride to 2 patients, olopatadine hydrochloride to 1 patient, fexofenadine hydrochloride to 1 patient, bepotastine besilate to 5 patients, levocetirizine hydrochloride to 3 patients, desloratadine to 1 patient, bilastine to 6 patients, rupatadine fumarate to 2 patients, and emedastine fumarate to 1 patient. As internasal corticosteroids, mometasone furoate hydrate was administered to 11 patients, fluticasone furoate to 4 patients, and dexamethasone cipecilate to 2 patients. As anti-LTs agent, pranlukast hydrate was administered to 1 patient

LTs leukotriene receptor antagonist, AHI apnea hypopnea index, CPAP continuous positive airway pressure, ESS Epworth Sleepiness Scale